HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acyltransferase inhibitors: a patent review (2010-present).

AbstractINTRODUCTION:
Acyltransferase (AT) catalyzes the transfer of an acyl moiety from acyl-coenzyme A (acyl-CoA) to an acceptor. ATs play important roles in the maintenance of homeostasis in the human body and have been linked to various diseases; therefore, several ATs have been proposed as potential targets for the treatment or prevention of such diseases. The AT family includes acyl-CoA:cholesterol AT (ACAT), diacylglycerol AT (DGAT), and monoacylglycerol AT (MGAT) for the metabolism of lipids. Furthermore, recent molecular biological studies revealed the existence of their isozymes with distinct functions in the body.
AREAS COVERED:
This review summarized patent filings published between 2010 and the present date that claimed isozyme-selective inhibitors of ACAT, DGAT and MGAT, which are involved in neutral lipid metabolism.
EXPERT OPINION:
Isozymes of ACAT, DGAT and MGAT play distinct functions in neutral lipid metabolism in the human body and have been considered as potential therapeutic targets. Accordingly, isozyme-selective inhibitors that could be used in the treatment or prevention of lipid metabolism disorders were searched for. Of these, pyripyropene A derivatives, ACAT2-selective inhibitors, may be potential therapeutics for the treatment of atherosclerosis, homozygous familial hypercholesterolemia and nonalcoholic fatty liver disease.
AuthorsTaichi Ohshiro, Hiroshi Tomoda
JournalExpert opinion on therapeutic patents (Expert Opin Ther Pat) Vol. 25 Issue 2 Pg. 145-58 (Feb 2015) ISSN: 1744-7674 [Electronic] England
PMID25470667 (Publication Type: Journal Article, Review)
Chemical References
  • Isoenzymes
  • Acyltransferases
Topics
  • Acyltransferases (antagonists & inhibitors)
  • Animals
  • Atherosclerosis (drug therapy, enzymology)
  • Drug Design
  • Humans
  • Hyperlipoproteinemia Type II (drug therapy, enzymology)
  • Isoenzymes
  • Lipid Metabolism (drug effects)
  • Molecular Targeted Therapy
  • Non-alcoholic Fatty Liver Disease (drug therapy, enzymology)
  • Patents as Topic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: